1006 related articles for article (PubMed ID: 29096860)
1. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
2. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
Hohenstein B; Tselmin S; Bornstein SR; Julius U
Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
4. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
5. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
6. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
Klaus G; Taylan C; Büscher R; Schmitt CP; Pape L; Oh J; Driemeyer J; Galiano M; König J; Schürfeld C; Spitthöver R; Schaefer JR; Weber LT; Heibges A; Klingel R
Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
8. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
10. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
11. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
12. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with statin intolerance.
Fischer S; Julius U
Atheroscler Suppl; 2017 Nov; 30():33-37. PubMed ID: 29096858
[TBL] [Abstract][Full Text] [Related]
14. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
16. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
[TBL] [Abstract][Full Text] [Related]
17. Familial hypercholesterolemia treatments: Guidelines and new therapies.
Raal FJ; Hovingh GK; Catapano AL
Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
20. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Spitthöver R; Röseler T; Julius U; Heigl F; Schettler VJJ; Kühn R; Leebmann J; Raabe A; Knittel M; Schürfeld C; Moesenthin M; Bernhardt WM; Röseler E; Ketteler M; Heibges A; Klingel R
J Clin Apher; 2019 Aug; 34(4):423-433. PubMed ID: 30817043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
